BRPI0915367B8 - peptídeo anti-p2x7 - Google Patents

peptídeo anti-p2x7

Info

Publication number
BRPI0915367B8
BRPI0915367B8 BRPI0915367A BRPI0915367A BRPI0915367B8 BR PI0915367 B8 BRPI0915367 B8 BR PI0915367B8 BR PI0915367 A BRPI0915367 A BR PI0915367A BR PI0915367 A BRPI0915367 A BR PI0915367A BR PI0915367 B8 BRPI0915367 B8 BR PI0915367B8
Authority
BR
Brazil
Prior art keywords
peptides
antibodies
epitope
cancer
peptide
Prior art date
Application number
BRPI0915367A
Other languages
English (en)
Portuguese (pt)
Inventor
Gidley-Baird Angus
Alexander Barden Julian
Original Assignee
Biosceptre International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903451A external-priority patent/AU2008903451A0/en
Application filed by Biosceptre International Ltd filed Critical Biosceptre International Ltd
Publication of BRPI0915367A2 publication Critical patent/BRPI0915367A2/pt
Publication of BRPI0915367B1 publication Critical patent/BRPI0915367B1/pt
Publication of BRPI0915367B8 publication Critical patent/BRPI0915367B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0915367A 2008-07-04 2009-07-03 peptídeo anti-p2x7 BRPI0915367B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008903451 2008-07-04
AU2008903451A AU2008903451A0 (en) 2008-07-04 Composite peptide
PCT/AU2009/000869 WO2010000041A1 (en) 2008-07-04 2009-07-03 Anti- p2x7 peptides and epitopes

Publications (3)

Publication Number Publication Date
BRPI0915367A2 BRPI0915367A2 (pt) 2015-11-03
BRPI0915367B1 BRPI0915367B1 (pt) 2020-10-13
BRPI0915367B8 true BRPI0915367B8 (pt) 2021-05-25

Family

ID=41465424

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915367A BRPI0915367B8 (pt) 2008-07-04 2009-07-03 peptídeo anti-p2x7

Country Status (12)

Country Link
US (3) US8597643B2 (OSRAM)
EP (1) EP2318438B1 (OSRAM)
JP (2) JP5701752B2 (OSRAM)
KR (1) KR101701300B1 (OSRAM)
CN (1) CN102143978B (OSRAM)
AU (1) AU2009266430B2 (OSRAM)
BR (1) BRPI0915367B8 (OSRAM)
CA (1) CA2729868C (OSRAM)
ES (1) ES2610225T3 (OSRAM)
IL (2) IL210220A (OSRAM)
NZ (1) NZ590146A (OSRAM)
WO (1) WO2010000041A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1961767B1 (en) 2001-01-17 2012-03-07 Biosceptre International Limited Diagnosis and treatment of cancers and other conditions
JP5624885B2 (ja) 2007-09-14 2014-11-12 バイオセプター・インターナショナル・リミテッド 細胞外体液中のプリン作動性（ｐ２ｘ）受容体
CA2737126C (en) * 2007-09-14 2018-05-01 Biosceptre International Limited Novel p2x7 epitopes
BRPI0915367B8 (pt) 2008-07-04 2021-05-25 Biosceptre International Ltd peptídeo anti-p2x7
JP5936067B2 (ja) 2009-08-20 2016-06-15 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 抗ｐ２ｘ７受容体抗体およびその断片
US8835609B2 (en) 2009-12-24 2014-09-16 Biosceptre International Limited Antigen binding sites to non-functional oligomeric P2X7 receptors and methods of use thereof
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
AU2012278921B2 (en) 2011-07-01 2016-11-10 Biosceptre International Limited Combination therapy
WO2016154683A1 (en) * 2015-04-02 2016-10-06 Biosceptre (Uk) Limited Pain treatment
ES2848478T3 (es) 2015-09-11 2021-08-09 Biosceptre Uk Ltd Receptores quiméricos para antígenos y usos de estos
EP3528789A4 (en) 2016-10-21 2020-06-24 Biosceptre UK Limited CYTOTOXIC PARTICLES
CA3213042A1 (en) * 2021-04-08 2022-10-13 Patrick Schlegel Methods for controlling immune cell activity
EP4587465A1 (en) * 2022-09-14 2025-07-23 Biosceptre (Aust) Pty Ltd Enrichment of engineered immune cells
EP4587464A1 (en) * 2022-09-14 2025-07-23 Biosceptre (Aust) Pty Ltd Methods of detecting immune cells
AU2023343786A1 (en) * 2022-09-14 2025-02-20 Biosceptre (Aust) Pty Ltd In vivo detection of immune cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
US5985603A (en) 1994-05-27 1999-11-16 Glaxo Group Limited P2x receptor DNA and protein sequence
EP0854923A2 (en) 1995-08-09 1998-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
EP0907729A1 (en) 1996-04-30 1999-04-14 Smithkline Beecham Plc HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) * 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
DK1086223T3 (da) * 1998-06-01 2009-11-30 Agensys Inc Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
WO2001030964A2 (en) 1999-10-22 2001-05-03 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AU2001274902A1 (en) * 2000-12-06 2002-06-18 Linex Technologies, Inc. Efficient sharing of capacity by remote stations using circuit switching and packet switching
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
EP1961767B1 (en) 2001-01-17 2012-03-07 Biosceptre International Limited Diagnosis and treatment of cancers and other conditions
NZ565994A (en) * 2001-09-03 2010-02-26 Intreat Pty Ltd Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions
WO2004092384A2 (en) 2003-04-17 2004-10-28 Affectis Pharmaceuticals Ag Means and methods for diagnosing and treating affective disorders
CA2607541A1 (en) * 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100036101A1 (en) * 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
JP5624885B2 (ja) * 2007-09-14 2014-11-12 バイオセプター・インターナショナル・リミテッド 細胞外体液中のプリン作動性（ｐ２ｘ）受容体
CA2737126C (en) 2007-09-14 2018-05-01 Biosceptre International Limited Novel p2x7 epitopes
BRPI0915367B8 (pt) 2008-07-04 2021-05-25 Biosceptre International Ltd peptídeo anti-p2x7
JP5936067B2 (ja) * 2009-08-20 2016-06-15 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 抗ｐ２ｘ７受容体抗体およびその断片
US8835609B2 (en) 2009-12-24 2014-09-16 Biosceptre International Limited Antigen binding sites to non-functional oligomeric P2X7 receptors and methods of use thereof
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
AU2012278921B2 (en) 2011-07-01 2016-11-10 Biosceptre International Limited Combination therapy

Also Published As

Publication number Publication date
IL232394A0 (en) 2014-06-30
AU2009266430B2 (en) 2014-08-14
EP2318438A1 (en) 2011-05-11
ES2610225T3 (es) 2017-04-26
IL232394A (en) 2016-04-21
US20110110959A1 (en) 2011-05-12
JP2015038144A (ja) 2015-02-26
IL210220A0 (en) 2011-03-31
CA2729868A1 (en) 2010-01-07
CN102143978A (zh) 2011-08-03
KR101701300B1 (ko) 2017-02-01
CA2729868C (en) 2018-07-10
US8597643B2 (en) 2013-12-03
US10238716B2 (en) 2019-03-26
AU2009266430A1 (en) 2010-01-07
AU2009266430A8 (en) 2011-03-10
JP5701752B2 (ja) 2015-04-15
CN102143978B (zh) 2015-02-18
WO2010000041A1 (en) 2010-01-07
US9328155B2 (en) 2016-05-03
KR20110031222A (ko) 2011-03-24
US20160199442A1 (en) 2016-07-14
IL210220A (en) 2016-04-21
US20140135475A1 (en) 2014-05-15
JP2011526249A (ja) 2011-10-06
BRPI0915367A2 (pt) 2015-11-03
EP2318438A4 (en) 2012-11-21
EP2318438B1 (en) 2016-11-02
BRPI0915367B1 (pt) 2020-10-13
NZ590146A (en) 2012-09-28

Similar Documents

Publication Publication Date Title
BRPI0915367B8 (pt) peptídeo anti-p2x7
ES2560532T3 (es) Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
CY1120144T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
ECSP13013102A (es) Dominios no inmunizados que se unen al suero y su uso para extender la vida media en el suero
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
CL2013002888A1 (es) Anticuerpo que se une peptido antigenico que se obtiene a partir de una proteina tau; composicion farmaceutica que comprende; uso para tratar trastorno o enfermedad neurodegenerativa;kit de ensayo, linea celular (div 2457-2011).
MX2013007371A (es) Peptidos de enlace her2 radiomarcados.
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
BRPI0908496A2 (pt) inibição de angiogênese
PE20131376A1 (es) Anticuerpos para metaloproteinasa-9 de matriz
MX2021009793A (es) Constructos de anticuerpo para dll3 y cd3.
CL2014001297A1 (es) Anticuerpo multivalente que tiene al menos dos dominios de unión a receptores para dos diferentes sitios de unión de un receptor diana lrp6; anticuerpo aislado biparatopico que une lrp6; anticuerpo igg biparatópico; secuencia nucleotídica que los codifica; vector; composición farmacéutica que los comprende; y uso para tratar cáncer que exprese lrp6 (div. sol. n°3093-12).
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
BR112015020587A2 (pt) proteínas de fusão de apelina e suas utilizações
EP3587439A3 (en) Improved quantification of vaccine compositions
CY1118928T1 (el) Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους
CO6630173A2 (es) Moléculas de unión a seroalbuminae
GT201200271A (es) Proteínas que se unen al tnf-a
CL2014000400A1 (es) Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
CR20130609A (es) Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase 1
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
UA113712C2 (xx) Антитіло до fap і способи його застосування
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
BR112015004022A2 (pt) aminoácidos modificados compreendendo um grupo azido

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF